Actively Recruiting
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
Led by Jonsson Comprehensive Cancer Center · Updated on 2025-12-19
200
Participants Needed
1
Research Sites
574 weeks
Total Duration
On this page
Sponsors
J
Jonsson Comprehensive Cancer Center
Lead Sponsor
V
Viewray Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
With people living longer after being treated for prostate cancer, quality of life has become a concern when considering the treatment plan. Sometimes after radiation therapy, patients may experience problems that affect the urinary and bowel systems, along with sexual function. Stereotactic body radiotherapy (SBRT) is a type of radiation technique that delivers five high doses of radiation. At University of California at Los Angeles (UCLA), we have the option to administer SBRT in both our CT-guided and MRI-guided radiation machines. This trial aims to determine the most effective method for protecting the nerves and blood vessels essential for erectile function, utilizing a technique known as neurovascular sparing. This technique uses images (i.e., MRI) to map the neurovascular bundles of nerves and blood vessels, which are crucial for erectile function. "Adapting" the radiotherapy treatment for each of these five treatment sessions could enable a more precise delivery of your radiation treatment that is customized based on your internal anatomy immediately before the treatment starts. This is also a standard and low-risk intervention used in many different types of cancer. However, it is a very labor-intensive and time-consuming procedure that requires a team of experts to work together before each of your radiotherapy sessions. We are unsure if the increased complexity associated with this adaptive treatment reduces side effects.
CONDITIONS
Official Title
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histologically confirmed, clinically localized adenocarcinoma of the prostate
- Staging workup according to National Comprehensive Cancer Network guidelines based on risk grouping
- Advanced imaging such as PSMA PET/CT or fluciclovine PET/CT allowed instead of bone scan if done first
- No metastatic disease above the renal artery bifurcation; nodal disease below is allowed
- Eastern Cooperative Oncology Group performance status 0 to 2
- Ability to undergo magnetic resonance angiography of the pelvis
- No urgent or emergency need for radiation therapy
- Ability to provide informed consent and comply with study requirements
You will not qualify if you...
- Neuroendocrine or small cell carcinoma of the prostate
- Evidence of distant metastases except nodal disease below renal arteries
- Intraprostatic lesion in the middle third or both lateral thirds of prostate
- History of whole-gland cryosurgery, high-intensity focused ultrasound, brachytherapy, or other ablative prostate treatments
- Prior pelvic radiotherapy
- History of Crohn's disease, ulcerative colitis, or ataxia telangiectasia
- Presence of penile prosthesis or implant before treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California at Los Angeles
Los Angeles, California, United States, 90045
Actively Recruiting
Research Team
C
Christy Palodichuk
CONTACT
C
Care Felix
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here